SG11202012608VA - Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile - Google Patents

Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile

Info

Publication number
SG11202012608VA
SG11202012608VA SG11202012608VA SG11202012608VA SG11202012608VA SG 11202012608V A SG11202012608V A SG 11202012608VA SG 11202012608V A SG11202012608V A SG 11202012608VA SG 11202012608V A SG11202012608V A SG 11202012608VA SG 11202012608V A SG11202012608V A SG 11202012608VA
Authority
SG
Singapore
Prior art keywords
binder
active agent
directed against
improved activity
activity profile
Prior art date
Application number
SG11202012608VA
Inventor
Sarah Johannes
Hans-Georg Lerchen
Beatrix Stelte-Ludwig
Pascale Lejeune
Hannah Jörissen
Christoph Mahlert
Simone Greven
Stephan Märsch
Stefanie Hammer
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SG11202012608VA publication Critical patent/SG11202012608VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202012608VA 2018-06-18 2019-06-13 Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile SG11202012608VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18178299 2018-06-18
PCT/EP2019/065517 WO2019243159A1 (en) 2018-06-18 2019-06-13 Binder-drug conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile

Publications (1)

Publication Number Publication Date
SG11202012608VA true SG11202012608VA (en) 2021-02-25

Family

ID=62705502

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012608VA SG11202012608VA (en) 2018-06-18 2019-06-13 Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile

Country Status (13)

Country Link
US (1) US20210275686A1 (en)
EP (1) EP3806908A1 (en)
JP (1) JP2021527640A (en)
KR (1) KR20210033470A (en)
CN (1) CN112601553A (en)
AU (1) AU2019289506A1 (en)
BR (1) BR112020025718A2 (en)
CA (1) CA3103327A1 (en)
EA (1) EA202190059A1 (en)
IL (1) IL279400A (en)
MX (1) MX2020013832A (en)
SG (1) SG11202012608VA (en)
WO (1) WO2019243159A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017017138A (en) 2015-06-23 2018-04-30 Bayer Pharma AG Targeted conjugates of ksp inhibitors.
WO2017162663A1 (en) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN109310781A (en) 2016-06-15 2019-02-05 拜耳制药股份公司 Specific antibody-drug-conjugate (ADC) with KSP inhibitor and anti-CD123- antibody
JP7030811B2 (en) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Specific antibody with KSP inhibitor-drug conjugate (ADC)
JP7066714B2 (en) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト Antibody drug conjugate (ADC) with an enzymatically cleavable group
TW202216771A (en) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 Ccr8 antibodies for therapeutic applications
JP2024503908A (en) 2021-01-22 2024-01-29 バイエル アクチェンゲゼルシャフト LRRC15 antibody and its conjugate

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
GB8905592D0 (en) 1989-03-10 1989-04-19 Gkn Technology Ltd Automatic length adjuster
ATE144793T1 (en) 1989-06-29 1996-11-15 Medarex Inc BISPECIFIC REAGENTS FOR AIDS THERAPY
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
DE69130709T3 (en) 1990-10-05 2005-12-22 Celldex Therapeutics, Inc. TARGETED IMMUNOSTIMULATION WITH SPECIFIC SUBSTANCES
DE69128253T2 (en) 1990-10-29 1998-06-18 Chiron Corp SPECIFIC ANTIBODIES, METHOD FOR THEIR PRODUCTION AND THEIR USE
EP0511011B1 (en) 1991-04-26 1996-10-23 Surface Active Limited Novel antibodies and methods for their use
ATE239506T1 (en) 1992-03-05 2003-05-15 Univ Texas USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND/OR THERAPY OF VASCULARIZED TUMORS
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
WO2003060064A2 (en) 2001-07-12 2003-07-24 Incyte Genomics, Inc. Intracellular signaling molecules
SG114505A1 (en) 2001-10-17 2005-09-28 First Cube Pte Ltd System and method for facilitating delivery and return service
DE60232994D1 (en) 2001-12-06 2009-08-27 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
EP1620092A4 (en) 2003-05-07 2008-04-16 Cytokinetics Inc Compounds, compositions, and methods
EP3120861B1 (en) 2003-11-06 2018-08-15 Seattle Genetics, Inc. Intermediate for conjugate preparation comprising auristatin derivatives and a linker
KR20060127413A (en) 2003-11-25 2006-12-12 카이론 코포레이션 Quinazolinone compounds as anticancer agents
US7662581B1 (en) 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
AU2005258135B2 (en) 2004-06-18 2011-09-22 Novartis Vaccines And Diagnostics Inc. N- (1- (1-benzyl -4-phenyl-1H-imidazol-2-YL) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
WO2006060737A2 (en) 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
DOP2006000277A (en) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp ANTI MN ANTIBODIES AND METHODS FOR USE
NZ577727A (en) 2007-01-05 2012-03-30 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
MX2010001975A (en) * 2007-08-29 2010-03-10 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses.
BR112013031819B1 (en) 2011-06-10 2022-05-03 Mersana Therapeutics, Inc Polymeric support, pharmaceutical composition, compound and support use
JP2016516035A (en) 2013-03-15 2016-06-02 ノバルティス アーゲー Cell growth inhibitors and their conjugates
KR20160003804A (en) * 2013-05-02 2016-01-11 아레스 트레이딩 에스.아. Monoclonal antibody directed against cxcr5
CA2934617A1 (en) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
CN107635586B (en) 2014-12-15 2021-09-24 拜耳医药股份有限公司 Antibody-drug conjugates (ADC) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies
BR112017027813A2 (en) * 2015-06-22 2018-08-28 Bayer Pharma Aktiengesellschaft binding agent-drug conjugates (adcs) and binding agent-prodrug conjugates (apds) having enzymatically cleavable groups
WO2017162663A1 (en) * 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
JP7066714B2 (en) * 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト Antibody drug conjugate (ADC) with an enzymatically cleavable group

Also Published As

Publication number Publication date
EA202190059A1 (en) 2021-04-21
IL279400A (en) 2021-01-31
CA3103327A1 (en) 2019-12-26
JP2021527640A (en) 2021-10-14
EP3806908A1 (en) 2021-04-21
MX2020013832A (en) 2021-03-25
BR112020025718A2 (en) 2021-04-06
WO2019243159A1 (en) 2019-12-26
KR20210033470A (en) 2021-03-26
CN112601553A (en) 2021-04-02
AU2019289506A1 (en) 2021-02-04
US20210275686A1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
IL279400A (en) Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
WO2019236567A8 (en) Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
MX2015009056A (en) Lna oligonucleotide carbohydrate conjugates.
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3411074A4 (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
EP3873486A4 (en) Bivalent targeted conjugates
MX368678B (en) Self-stabilizing linker conjugates.
EP3946460A4 (en) Improved conjugation linkers
EP3769786A4 (en) Antibody-drug conjugate having acidic self-stabilization junction
EP3838893A4 (en) Linker, antibody-drug conjugate including same, and use thereof
EP3936150A4 (en) Antibody-drug conjugates including antibody against human dlk1, and use thereof
WO2016127081A8 (en) Antibody drug conjugates
IL287391A (en) Amatoxin antibody-drug conjugates and uses thereof
WO2014134457A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
IL286847A (en) Hsp90-binding conjugates and formulations thereof
MX2019009229A (en) Novel nicotine degrading enzyme variants.
IL285953A (en) Antibody-drug conjugates including antibody against human dlk1, and use thereof
IL292766A (en) Antibody-drug conjugates targeting claudin 18.2
WO2014134486A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
EP3620471A4 (en) Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate
EP3970511A4 (en) Strain showing liver function improving activity, and use thereof
IL291312A (en) Anti-ptcra antibody-drug conjugates and uses thereof
IL290301A (en) Il-15 conjugates and uses thereof
SG11202111175YA (en) Slow-release cytokine conjugates
EP3908129A4 (en) Aerosol-generating article including first wrapper and second wrapper, and aerosol-generating system using the aerosol-generating article